The Use of Flavonoids in Central Nervous System Disorders

被引:71
|
作者
Grosso, C. [1 ]
Valentao, P. [1 ]
Ferreres, F. [2 ]
Andrade, P. B. [1 ]
机构
[1] Univ Porto, REQUIMTE Lab Farmacognosia, Dept Quim, Fac Farm, P-4050313 Oporto, Portugal
[2] CEBAS CSIC, Dept Food Sci & Technol, Res Grp Qual Safety & Bioact Plant Foods, Murcia 30100, Spain
关键词
Alzheimer's disease; CNS; depression; epilepsy; Parkinson's disease; natural antioxidants; phenolic compounds; schizophrenia; ROTENONE-INDUCED APOPTOSIS; ST-JOHNS-WORT; ANTIDEPRESSANT-LIKE ACTIVITY; IMPROVES MEMORY IMPAIRMENT; BIOASSAY-GUIDED ISOLATION; GREEN TEA POLYPHENOLS; BLOOD-BRAIN-BARRIER; MONOAMINE-OXIDASE-B; OXIDATIVE STRESS; ALZHEIMERS-DISEASE;
D O I
10.2174/09298673113209990155
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurodegenerative, neurological and psychiatric diseases are a group of pathologies with huge social and economic impacts. Since brain disorders continue to be pathological conditions for which corrective surgery cannot be widely used, treatments are based on drugs that only alleviate the symptoms. Despite all efforts in finding more efficient therapeutic agents, the requirement for neuroprotective drugs able to cross the blood-brain barrier (BBB) has been a hard challenge to overcome. Flavonoids are known by their antioxidant activities thus preventing oxidative stress, which is believe to be one of the causes of disorders affecting the central nervous system. Moreover, they can also modulate both enzymes and receptors activities, being regarded as multi-target botanical therapeutics or drugs. This review will give emphasis to the benefits of flavonoids found in the diet in the treatment of Alzheimer's disease, Parkinson's disease, epilepsy, depression, and schizophrenia. The antioxidant effect of several flavonoids, as well as their effects not related with antioxidant activity, in the above mentioned diseases will be reviewed. Aspects concerning structure-activity relationships, but also the bioavailability of these compounds in the brain will be referred.
引用
收藏
页码:4694 / 4719
页数:26
相关论文
共 50 条
  • [31] LIPID STORAGE DISORDERS OF CENTRAL NERVOUS SYSTEM
    LEISTYNA, JA
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1962, 104 (06): : 680 - +
  • [32] THE FUNDUS OF THE EYE IN DISORDERS OF THE CENTRAL NERVOUS SYSTEM
    RUCKER, CW
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1946, 131 (04): : 321 - 321
  • [33] Role of Adiponectin in Central Nervous System Disorders
    Bloemer, Jenna
    Pinky, Priyanka D.
    Govindarajulu, Manoj
    Hong, Hao
    Judd, Robert
    Amin, Rajesh H.
    Moore, Timothy
    Dhanasekaran, Muralikrishnan
    Reed, Miranda N.
    Suppiramaniam, Vishnu
    NEURAL PLASTICITY, 2018, 2018
  • [34] Central nervous system manifestations of mitochondrial disorders
    Finsterer, J.
    ACTA NEUROLOGICA SCANDINAVICA, 2006, 114 (04): : 217 - 238
  • [35] Headache and inflammatory disorders of the central nervous system
    La Mantia, L
    Erbetta, A
    NEUROLOGICAL SCIENCES, 2004, 25 (Suppl 3) : S148 - S153
  • [36] NK Cells in Central Nervous System Disorders
    Poli, Aurelie
    Kmiecik, Justyna
    Domingues, Olivia
    Hentges, Francois
    Blery, Mathieu
    Chekenya, Martha
    Boucraut, Jose
    Zimmer, Jacques
    JOURNAL OF IMMUNOLOGY, 2013, 190 (11): : 5355 - 5362
  • [37] Microdialysis in central nervous system disorders and their treatment
    McAdoo, David J.
    Wu, Ping
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2008, 90 (02) : 282 - 296
  • [38] The role of microbiome in central nervous system disorders
    Wang, Yan
    Kasper, Lloyd H.
    BRAIN BEHAVIOR AND IMMUNITY, 2014, 38 : 1 - 12
  • [39] Proteomic approaches to central nervous system disorders
    Rohlff, C
    Southan, C
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2002, 4 (03) : 251 - 258
  • [40] Neonatal central nervous system vascular disorders
    Burrows, PE
    Robertson, RL
    NEUROSURGERY CLINICS OF NORTH AMERICA, 1998, 9 (01) : 155 - +